Connect with the Tandem Mobi system
The Tandem Mobi system is now powered by Control-IQ+ technology —the only predictive algorithm with AutoBolus. The best Tandem algorithm ever pairs with Dexcom's most accurate CGM1-2 to predict and help prevent highs and lows for more time in range. Now available for ages 2+.
Control-IQ+ Technology
Control-IQ+ offers unique and enhanced features for more targeted control. It’s the only predictive algorithm with AutoBolus—which includes a 30-minute prediction and automatically adjusts insulin delivery every 5-minutes to help protect from highs and lows. Now available for ages 2+.
Sleep Activity Setting
Only Tandem pumps have a dedicated Sleep Activity, which is designed to help protect from overnight lows and morning highs with fewer disruptions from alerts and alarms
AutoBolus
AutoBolus* is designed to help prevent highs and cover missed meal boluses
*If glucose values are predicted to be above 180 mg/dL (or 10.0 mmol/L), Control-IQ+ technology calculates a correction bolus using the Personal Profile settings and a target of 110 mg/dL (or 6.1 mmol/L) and delivers 60% of that value.
Trusted partners in diabetes management
Dexcom and Tandem have created life-changing3 diabetes management solutions with over a decade of collaboration.
Dexcom G7
- The most accurate CGM system1,2
- The only CGM that offers no fingersticks* from day 1
- 60% smaller§
- The fastest CGM—only 30-minute warmup||
- The only CGM with an Urgent Low Soon alert¶, notifying patients of a severe low up to 20 minutes before it happens.
¶ Audible and visual notification of predictive alert at 55 mg/dL within 20 minutes. *Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings.
Tandem Mobi
- The world's smallest durable AID system7
- Wearability like never before†–wear it (on body),† clip it (to clothes), slip it (in pocket)
- Pump button for checking the pump status lights and to give a Quick Bolus
- Control-IQ+ uses Dexcom G7 glucose values to predict and help prevent from highs and lows, providing continuous automation
- Create up to six Personal Profiles based on insulin needs
†Do not wear or place your pump more than 12 inches (30.5 cm) above your infusion site. Doing so may result in over delivery of insulin. ‡Adhesive sleeve sold separately
Meet Dexcom CGM
Meet Dexcom CGM, you have the freedom to choose the insulin pump that works best for you. Glucose readings are sent to your smartphone‡‡ or Dexcom receiver—without fingersticks.*
*Fingersticks required for diabetes treatment decision if symptoms or expectations do not match readings.
Do you have questions about the Tandem Mobi system?
†Bolus delivery from the t:connect mobile app requires a compatible smartphone model and operating system, an app update, a remote software update on the customer’s t:slim X2 insulin pump and additional training. Only available to Tandem Diabetes Care customers who reside in the United States. ‡‡Smart device sold separately. For a list of compatible devices, visit dexcom.com/compatibility. §Compared to prior generation Dexcom CGM system. ||Dexcom G7 can complete warmup within 30 minutes, whereas other CGM brands require up to an hour or longer.
1 U.S. Food and Drug Administration, 510(k) Substantial Equivalence Determination Decision Summary, K213919. Published December 7, 2022. https://www.accessdata.fda.gov/cdrh_docs/reviews/K213919.pdf. 2 U.S. Food and Drug Administration, 510(k) Substantial Equivalence Determination Decision Summary, K222447. Published March 3, 2023. https://www.accessdata.fda.gov/cdrh_docs/reviews/K222447.pdf.
3 Brown SA, et al. N Engl J Med. 2019.381(18).1707-17. 6 Criego AB, Carlson AL, Brown SA, et al. Diabetes Technol Ther. 2024;26(1):11-23. doi:10.1089/dia.2023.0364. 7 As of Feb. 2024. Data on file, Tandem Diabetes Care.
BRIEF SAFETY STATEMENT: Failure to use the Dexcom Continuous Glucose Monitoring System and its components according to the instructions for use provided with your device and available at https://www.dexcom.com/safety-information and to properly consider all indications, contraindications, warnings, precautions, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose) occurrence and/or making a treatment decision that may result in injury. If your glucose alerts and readings from the Dexcom CGM do not match symptoms, use a blood glucose meter to make diabetes treatment decisions. Seek medical advice and attention when appropriate, including for any medical emergency.
RX ONLY. The Tandem Mobi insulin pump with interoperable technology (the pump) and Control -IQ+ technology (Control-IQ+) are intended for single patient use. The pump and Control-IQ+ are indicated for use with NovoLog or Humalog U-100 insulin. Tandem Mobi system: The Tandem Mobi insulin pump is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in persons requiring insulin. The pump is able to reliably and securely communicate with compatible, digitally connected devices, including automated insulin dosing software, to receive, execute, and confirm commands from these devices. The pump is indicated for use in persons 2 years of age and greater.
Control-IQ+ technology: Control-IQ+ technology is intended for use with compatible integrated continuous glucose monitors (iCGM, sold separately) and alternate controller enabled (ACE) pumps to automatically increase, decrease, and suspend delivery of basal insulin based on iCGM readings and predicted glucose values. It can also deliver correction boluses when the glucose value is predicted to exceed a predefined threshold. Control-IQ+ technology is intended for the management of type 1 diabetes mellitus in persons 2 years of age and greater and of type 2 diabetes mellitus in persons 18 years of age and greater.
WARNING: Control-IQ+ technology should not be used in anyone under the age of 2 years old with type 1 diabetes or under the age of 18 years old with type 2 diabetes. It should also not be used in patients who require less than a total daily insulin dose of 5 units of insulin per day or who weigh less than 20 pounds (9 kilograms), as those are the required minimum values needed for Control -IQ+ to operate safely.
Users of the pump and Control-IQ+ must: use the insulin pump, iCGM, and all other system components in accordance with their respective instructions for use. Failure to follow these instructions for use could result in an over delivery or under delivery of insulin. This can cause hypoglycemia (low BG) or hyperglycemia (high BG) events. Visit tandemdiabetes.com/safetyinfo for additional important safety information.